KALV Stock Cash Flow Statements

KalVista Pharmaceuticals Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

KalVista Pharmaceuticals Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-07-31	2025-04-30	2025-01-31	2024-10-31	2024-07-31	2024-04-30	2024-01-31	2023-10-31	2023-07-31	2023-04-30	2023-01-31	2022-10-31	2022-07-31	2022-04-30	2022-01-31	2021-10-31	2021-07-31	2021-04-30	2021-01-31	2020-10-31	2020-07-31	2020-04-30	2020-01-31	2019-10-31	2019-07-31	2019-04-30	2019-01-31	2018-10-31	2018-07-31	2018-04-30	2018-01-31	2017-10-31	2017-07-31	2017-04-30	2016-09-30	2015-12-31	2015-09-30	2015-06-30	2015-03-31

cash flows from operating activities
net income	-60,096,000	-52,226,000	-48,508,000	-42,267,000	-40,443,000	-44,649,000	-29,028,000	-27,650,000	-25,317,000	-26,305,000	-21,303,000	-22,257,000	-23,042,000	-24,113,000	-22,468,000	-19,649,000	-16,109,000	-14,956,000	-10,047,000	-10,427,000	-10,814,000	-6,584,000	-9,291,000	-5,903,000	-7,338,000	-8,526,000	-3,956,000	-3,304,000	-5,030,000	-657,000	-5,234,000	-4,986,000	-4,928,000	-4,202,000	-2,386,000	-5,659,000	-4,991,000	-9,012,000	-5,184,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	252,000	261,000	229,000	227,000	224,000	219,000	207,000	197,000	193,000	188,000	199,000	173,000	158,000	156,000	149,000	127,000	132,000	140,000	136,000	133,000	128,000	130,000	134,000	127,000	121,000	122,000	103,000	103,000	50,000	51,000	50,000	47,000	32,000		0	35,000	33,000	34,000	31,000
stock-based compensation expense	5,379,000	3,642,000	2,610,000	2,999,000	3,040,000	12,743,000	2,711,000	3,207,000	3,254,000	2,441,000	2,333,000	2,506,000	2,642,000	2,654,000	2,777,000	2,860,000	2,795,000	3,441,000	1,241,000	1,248,000	1,188,000	1,090,000	1,122,000	1,162,000	1,074,000	846,000	797,000	976,000	347,000
realized gain from sale of marketable securities	-587,000									55,000	-1,000	69,000	16,000	285,000	176,000	97,000	23,000	39,000	-76,000	-46,000	-70,000
non-cash operating lease expense	218,000					-1,000	2,000	-19,000	6,000	32,000	10,000	19,000	23,000	26,000	107,000	24,000	22,000	89,000	8,000	9,000	8,000
amortization of premium on marketable securities	-7,000		1,000	5,000	5,000		5,000	21,000	62,000		212,000	287,000	391,000		657,000	671,000	753,000		110,000	69,000	68,000
foreign currency exchange gain	485,000					164,000	-215,000			-279,000	-600,000	-1,165,000	426,000	854,000	432,000	252,000	14,000
non-cash interest expense and amortization of issuance costs	3,453,000	2,948,000
fair value adjustment to derivative liability	1,100,000	1,600,000
changes in operating assets and liabilities:
research and development tax credit receivable	826,000			-1,068,000	-1,253,000	14,391,000	-2,106,000	-2,025,000	-2,084,000	-4,365,000	9,186,000	-3,567,000	-3,570,000	-3,724,000	5,775,000	-4,041,000	-3,211,000	-2,678,000	7,813,000	-2,140,000	4,462,000	-2,376,000	-2,828,000	1,483,000	-2,060,000	-2,474,000	-1,717,000	-1,611,000	919,000	-1,873,000	-986,000	-867,000	-530,000	703,000
accounts receivable	-1,926,000
prepaid expenses and other assets	1,597,000	-1,281,000	-1,398,000	2,104,000	-783,000	-1,444,000	145,000	1,764,000	-1,003,000	2,250,000	790,000	1,715,000	1,935,000	-5,621,000	-1,240,000
accounts payable	2,510,000	-1,392,000	779,000	-5,860,000	1,502,000	6,098,000	-1,941,000	55,000	108,000	3,018,000	-1,830,000	597,000	-678,000	1,459,000	-935,000	1,691,000	-528,000	1,332,000	-1,628,000	411,000	35,000	-1,137,000	691,000	-950,000	392,000	-214,000	-340,000	962,000	1,126,000	-331,000	687,000	-910,000	771,000	358,000	244,000	-148,000	-290,000	-218,000	1,011,000
accrued expenses	-8,199,000	8,115,000	3,053,000	5,037,000	-1,776,000	-2,435,000	2,870,000	4,014,000	-1,240,000	231,000	1,715,000	1,029,000	-1,043,000	751,000	505,000	217,000	-1,001,000	1,522,000	-1,874,000	797,000	538,000	718,000	-202,000	553,000	-1,117,000	2,248,000	351,000	-91,000	157,000	800,000	-33,000	550,000	-185,000	-371,000	-282,000	37,000	-394,000
deferred revenue	493,000																					-3,824,000	-1,577,000	-3,920,000	-3,369,000	-2,926,000	-3,890,000	-5,593,000	-3,718,000	-4,573,000
net cash from operating activities	-54,502,000	-40,364,000	-32,681,000	-39,642,000	-40,220,000	-15,105,000	-27,571,000	-19,825,000	-26,730,000	-22,636,000	-9,289,000	-20,594,000	-22,742,000	-26,789,000	-14,065,000	-19,545,000	-17,735,000	-11,045,000	-7,586,000	-7,952,000	-3,588,000	-12,618,000	-13,109,000	-7,814,000	-11,275,000	-10,511,000	-10,856,000	-8,786,000	-6,212,000	-5,955,000	28,220,000	-7,259,000	-4,448,000	-2,641,000	-1,616,000	-5,067,000	-5,306,000	-6,441,000	-4,049,000
capex	-290,000	-281,000	-24,000	-108,000	-21,000	-15,000	-19,000	-2,000	-6,000	-69,000	-15,000	-192,000	-920,000	-86,000	-202,000	-356,000	-287,000	-33,000	-14,000	-13,000	-22,000	-8,000	0	-114,000	-51,000	-275,000	-20,000	-221,000	-465,000	-1,084,000	-182,000	-51,000	-110,000	0	0	-379,000	-21,000	-79,000	-180,000
free cash flows	-54,792,000	-40,645,000	-32,705,000	-39,750,000	-40,241,000	-15,120,000	-27,590,000	-19,827,000	-26,736,000	-22,705,000	-9,304,000	-20,786,000	-23,662,000	-26,875,000	-14,267,000	-19,901,000	-18,022,000	-11,078,000	-7,600,000	-7,965,000	-3,610,000	-12,626,000	-13,109,000	-7,928,000	-11,326,000	-10,786,000	-10,876,000	-9,007,000	-6,677,000	-7,039,000	28,038,000	-7,310,000	-4,558,000	-2,641,000	-1,616,000	-5,446,000	-5,327,000	-6,520,000	-4,229,000
cash flows from investing activities
purchases of marketable securities	-19,979,000		-6,563,000	-1,000	-983,000		-18,150,000	-3,770,000	-25,767,000		-53,655,000	0	-10,102,000		-32,720,000	-32,659,000	-19,036,000		-7,472,000	-9,535,000	-9,807,000
sales and maturities of marketable securities	41,677,000		15,207,000	48,876,000	38,230,000		11,558,000	32,531,000	45,386,000		51,153,000	20,290,000	41,066,000		45,824,000	50,658,000	34,204,000		14,431,000	15,919,000	15,342,000
acquisition of property and equipment	-290,000	-281,000	-24,000	-108,000	-21,000	-15,000	-19,000	-2,000	-6,000	-69,000	-15,000	-192,000	-920,000	-86,000	-202,000	-356,000	-287,000	-33,000	-14,000	-13,000	-22,000	-8,000	0	-114,000	-98,000	-275,000	-20,000	-221,000	-565,000	-1,084,000	-182,000	-51,000	-110,000
capitalized website development costs	-147,000	-234,000	-103,000	-94,000	-64,000
net cash from investing activities	21,261,000	-3,328,000	8,517,000	48,673,000	37,162,000	-126,186,000	-6,702,000	28,556,000	19,613,000	-6,210,000	-2,517,000	20,098,000	30,044,000	12,434,000	12,902,000	17,643,000	14,881,000	-166,483,000	6,945,000	6,371,000	5,513,000	10,027,000	9,770,000	-1,514,000	-1,530,000	-14,047,000	-54,589,000	-221,000	-565,000	-1,084,000	-182,000	-51,000	-110,000	-7,000	0	-1,094,000	-21,000	-79,000	-180,000
cash flows from financing activities
proceeds from the royalty agreement	21,921,000
issuance of common stock from equity incentive plans	595,000	1,849,000	632,000	295,000	3,000,000	30,000	284,000	128,000	204,000	-33,000	146,000	168,000	168,000	138,000	772,000	63,000	608,000	1,374,000	55,000	60,000	46,000	2,000	44,000	138,000	32,000
issuance of common stock from employee stock purchase plan	694,000
net cash from financing activities	23,210,000	4,659,000	151,773,000	295,000	3,000,000	150,098,000	284,000	128,000	204,000	-33,000	57,813,000	168,000	168,000	138,000	772,000	63,000	608,000	210,308,000	1,703,000	60,000	46,000	1,000	45,000	138,000	11,400,000	155,000	56,000	82,784,000	4,948,000	-13,000	-52,000			0	5,000	6,000	-176,000	68,720,000	3,513,000
effect of exchange rate changes on cash and cash equivalents	2,723,000	3,364,000	-1,249,000	407,000	117,000	-74,000	-621,000	-602,000	84,000	68,000	457,000	1,050,000	-339,000	-628,000	-523,000	-13,000	-3,000	85,000	491,000	-319,000	254,000	-236,000	190,000	802,000	-494,000	64,000	618,000	-731,000	-1,156,000
net increase in cash, cash equivalents and restricted cash	-7,308,000
cash, cash equivalents and restricted cash at beginning of period	132,272,000
cash, cash equivalents and restricted cash at end of period	124,964,000
supplemental disclosures of non-cash activities:
right of use assets obtained in exchange for operating lease liabilities	725,000	458,000	0							0	0	0	1,192,000	0
reconciliation of cash, cash equivalents and restricted cash:
cash and cash equivalents	124,304,000
restricted cash, long-term	660,000
total cash, cash equivalents and restricted cash	124,964,000
cash flows from operating activities:
realized (gain) income from sale of marketable securities						-195,000	-221,000	-595,000	-314,000
amortization of premium on available for sale securities
other receivables
cash flows from investing activities:
purchases of available for sale securities																						-4,683,000	-2,553,000	-22,915,000	-19,646,000	-24,470,000
sales and maturities of available for sale securities																						14,718,000	12,323,000	21,515,000	18,214,000
cash flows from financing activities:
issuance costs associated with the royalty agreement
issuance of common stock, net of offering expenses		0																208,934,000				0					0
issuance of pre-funded warrants
net increase in cash and cash equivalents		-35,669,000	126,360,000	9,733,000	59,000	8,733,000	-34,610,000	8,257,000	-6,829,000	-28,811,000	46,464,000	722,000	7,131,000	-14,845,000	-914,000	-1,852,000	-2,249,000	32,865,000	1,553,000	-1,840,000	2,225,000	-2,826,000	-3,104,000			-24,339,000	-64,771,000			-7,623,000				-2,548,000	-1,611,000
cash and cash equivalents and restricted cash at beginning of year
cash and cash equivalents and restricted cash at end of year
supplemental disclosures of cash flow information:
website development costs included in accounts payable
non-cash operating lease benefit
foreign currency exchange loss
research and development tax credit
proceeds from royalty agreement
issuance costs associated with royalty agreement
realized (gain) from sale of marketable securities				-649,000	-317,000
non-cash operating lease (benefit) expense				-45,000	-5,000
foreign currency exchange (gain) loss									-395,000									-133,000	-273,000	264,000	-432,000
cash and cash equivalents at beginning of period				0	31,789,000		0	0	56,238,000		0	0	30,732,000		0	0	50,592,000		0	0	15,789,000		0	0	32,006,000		0	0	51,055,000		0	0	30,950,000		0		0	0	3,897,000
cash and cash equivalents at end of period				9,733,000	31,848,000		-34,610,000	8,257,000	49,409,000		46,464,000	722,000	37,863,000		-914,000	-1,852,000	48,343,000		1,553,000	-1,840,000	18,014,000		-3,104,000	-8,388,000	30,107,000		-64,771,000	73,046,000	48,070,000		30,550,000	1,672,000	26,456,000		-1,611,000		-5,503,000	62,200,000	3,181,000
foreign currency exchange					-414,000
cash and cash equivalents, beginning year
cash and cash equivalents, end of year
property and equipment included in accounts payable and accrued expenses
website development costs							-91,000
issuance of common stock, net of offering expenses of 0.3 million
issuance of pre-funded warrants, net of offering expenses
property and equipment included in accounts payable and accrued expenses:												-12,000	144,000		-20,000
finance lease principal payments
prepaid expenses and other current assets																	-625,000	-257,000	-2,996,000	1,730,000	1,301,000	-925,000	-972,000	224,000	561,000	496,000	-1,958,000	-448,000	-69,000	460,000	-570,000	-551,000	-85,000	608,000	533,000	349,000	43,000	-487,000	-437,000
other assets																														0					0	-58,000
acquisition of property and equipment in accounts payable																									47,000				100,000
grants and other receivables																														38,000	871,000
capital leases																														0	0	0	513,000
realized (gain) from available for sale securities
amortization of right of use assets																							145,000	135,000	138,000
amortization of discount/premium on available for sale securities																							57,000	44,000	35,000
lease obligations																							-145,000	-134,000	-137,000
capital lease principal payments																							1,000	0	-54,000	-54,000	-51,000	-52,000	-52,000	-50,000	-52,000
realized (gain) income from available for sale securities																								-100,000	-29,000
foreign currency remeasurement (gain) loss																															-531,000	-1,000	32,000
issuance of common stock, net of 123 of offering expenses																								0	11,422,000
foreign currency remeasurement loss																									454,000	-60,000	-246,000	220,000	6,000
net decrease in cash and cash equivalents																									-1,899,000				-2,985,000			1,672,000	-4,494,000						-716,000
supplemental disclosures of non-cash financing activities
changes in operating assets and liabilities, net of changes from business acquired:
cash acquired in transaction
proceeds from issuance of common stock, net of issuance costs of 4,390 in the year ended april 30, 2019
proceeds from issuance of common stock from exercise of stock options
conversion of preferred stock and ordinary shares to common stock
sales of available for sale securities
issuance of common stock from stock option exercises																											107,000
issuance of common stock																													5,000,000		0
proceeds from issuance of common stock																																		0		0	-176,000	67,964,000	120,000
proceeds from issuance of series b preferred stock, net of issuance costs
stock-based compensation																															285,000	273,000	221,000
effect of exchange rate changes on cash																															2,564,000	-69,000	64,000	100,000
conversion of preferred stock to common stock																																				0	0
due to related parties
grants receivable																																	224,000	-7,000
depreciation expense
share-based compensation expense
foreign currency exchange rate gain
cash acquired in carbylan transaction
purchases of property and equipment
proceeds from issuance of series a preferred stock, net of issuance costs
cash paid for taxes
foreign currency remeasurement gain
proceeds from issuance of redeemable convertible preferred stock
gain on sale of property and equipment																																			0
stock based compensation expense																																			282,000		289,000	37,000	118,000
change in fair value of preferred stock warrant liability and derivative liability																																				0	0	-2,000	-518,000
non-cash interest expense																																			0	37,000	35,000	73,000	84,000
amortization of loan and convertible promissory notes discount																																			0	7,000	15,000	51,000	707,000
loss on extinguishment of loans payable
loss on extinguishment of convertible promissory notes																																				0	0
impairment of long-lived assets																																			0
deferred licensing revenue																																			-7,000	-8,000	-7,000	-7,000	-7,000
purchase of property and equipment																																			0	-379,000	-21,000	-79,000	-180,000
sale of property and equipment																																			0
proceeds from issuance of common stock upon exercise of options																																			5,000	6,000	0
proceeds from convertible promissory notes																																						0	4,000,000
repayment of loan payable																																			0
supplemental cash flow information
cash paid for interest																																			0	135,000	0	1,000	44,000
supplemental disclosures of non-cash investing activities
transfer of long-term deposits to property and equipment																																			0
conversion of preferred stock warrants to common stock warrants																																				0	0
derivative related to convertible promissory notes at issuance
beneficial conversion feature for convertible promissory notes
loss on extinguishment of loan payable
increase accrual of deferred public offering costs
deferred public offering costs																																							-607,000
property and equipment additions in accounts payable and accrued expenses
accrual of deferred public offering costs
stock based compensation
deposit for leasehold improvements
proceeds from issuance of convertible preferred stock
proceeds from loans payable
repayment of loans payable
net increase/(decrease) in cash and cash equivalents																																				-6,155,000	-5,503,000
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
issuance of preferred stock warrants
increase of accrual for deferred public offering costs
increase of derivative related to convertible promissory notes
increase of beneficial conversion feature for convertible promissory notes																																				0	0
increase of derivative related to convertible promissory notes at issuance																																					0
accruals																																							146,000
derivative related to convertible promissory notes upon issuance																																							1,196,000
beneficial conversion feature of convertible promissory notes																																							158,000

We provide you with 20 years of cash flow statements for KalVista Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of KalVista Pharmaceuticals stock. Explore the full financial landscape of KalVista Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about KalVista Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.